WO2025104613 - ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS
National phase entry is expected:
Publication Number
WO/2025/104613
Publication Date
22.05.2025
International Application No.
PCT/IB2024/061280
International Filing Date
13.11.2024
Title **
[English]
ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS
[French]
INHIBITEURS D'ENT1 EN COMBINAISON AVEC DES INHIBITEURS DE POINTS DE CONTRÔLE
Applicants **
ITEOS BELGIUM SA
Inventors
SANDERS, Theodore J.
HOUTHUYS, Erica Joke Katelijne Heleen
CHABLE, Lucas
MARILLIER, Reece Gerrad
ROSSETTI, Maura
Priority Data
63/598,899
14.11.2023
US
63/562,953
08.03.2024
US
63/568,078
21.03.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 7454 | |
| EPO | Filing, Examination, Granting | 158442 | |
| Japan | Filing, Examination, Granting | 5057 | |
| South Korea | Filing, Examination, Granting | 10318 | |
| USA | Filing, Examination, Granting | 82140 |
Total:
263,411
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein are combinations, compositions, and kits comprising an ENT1 inhibitor and a checkpoint inhibitor. In some embodiments, the ENT1 inhibitor is a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, or solvate thereof. In some embodiments, the checkpoint inhibitor is a PD1 inhibitor, a PD-L1 inhibitor, a LAG- 3 inhibitor, and a CTLA-4 inhibitor. Also disclosed herein are methods comprising administering an ENT1 inhibitor and a checkpoint inhibitor as well as uses of an ENT1 inhibitor and a checkpoint inhibitor in the manufacture of a medicament. In some embodiments, the combinations, compositions, kits, methods, and uses further comprise an adenosine receptor antagonist.[French]
L'invention concerne des combinaisons, des compositions et des kits comprenant un inhibiteur d'ENT1 et un inhibiteur de point de contrôle. Dans certains modes de réalisation, l'inhibiteur d'ENT1 est un composé de formule (I) ou un sel, hydrate ou solvate pharmaceutiquement acceptable de celui-ci. Dans certains modes de réalisation, l'inhibiteur de point de contrôle est un inhibiteur de PD1, un inhibiteur de PD-L1, un inhibiteur de LAG-3 et un inhibiteur de CTLA-4. L'invention concerne également des méthodes comprenant l'administration d'un inhibiteur d'ENT1 et d'un inhibiteur de point de contrôle ainsi que des utilisations d'un inhibiteur d'ENT1 et d'un inhibiteur de point de contrôle dans la fabrication d'un médicament. Dans certains modes de réalisation, les combinaisons, compositions, kits, procédés et utilisations comprennent en outre un antagoniste du récepteur de l'adénosine.